
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
CTCL tumors can arise in patients with MF or in those with non-MF CTCL, who lack the typical MF signs of scaly patches or lesions. Almost all CTCL tumors present as bumps or ulcers.